Monoclonal antibody therapy of chronic lymphocytic leukemia

[1]  G. Denardo,et al.  Refractory Chronic Lymphocytic Leukemia , 2020, Definitions.

[2]  Z. Estrov,et al.  Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL. , 2007 .

[3]  M. Andreeff,et al.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Do,et al.  Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Cheson,et al.  Initial results from ongoing phase I trials of a novel pan bcl-2 family small molecule inhibitor , 2005 .

[6]  C. Fegan,et al.  Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Bociek,et al.  Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). , 2004 .

[8]  M. Hallek,et al.  FluCam—a New, 4-Weekly Combination of Fludarabine and Alemtuzumab for Patients with Relapsed Chronic Lymphocytic Leukemia. , 2004 .

[9]  A. Chanan-Khan,et al.  A Pilot Study of Genasense® (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. , 2004 .

[10]  H. Kantarjian,et al.  Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLL. , 2004 .

[11]  H. Döhner,et al.  Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG). , 2004 .

[12]  V. Rossi,et al.  Alemtuzumab as Consolidation after a Response to Fludarabine Is Effective To Purge Residual Disease in Patients with Chronic Lymphocytic Leukemia. , 2004 .

[13]  J. Degen,et al.  Hemostatic Factors Contribute to Tumor Cell Metastatic Potential by a Mechanism Linked to Natural Killer Cell Function. , 2004 .

[14]  E. Kimby,et al.  Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. , 2004, Blood.

[15]  E. Remmerswaal,et al.  Autologous cytomegalovirus‐specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia , 2004, British journal of haematology.

[16]  H. Döhner,et al.  Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) , 2004, Leukemia.

[17]  Lisa L. Smith,et al.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. , 2004, Blood.

[18]  S. Richards,et al.  Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. , 2004, Blood.

[19]  P. Brossart,et al.  Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. , 2004, Blood.

[20]  L. Gordon,et al.  A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL) , 2004, Leukemia & lymphoma.

[21]  H. Kantarjian,et al.  Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia , 2003, Cancer.

[22]  J. Hainsworth,et al.  Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Andreeff,et al.  Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. , 2003, Blood.

[24]  D. Spaner,et al.  Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  B. Cheson.  Radioimmunotherapy of non-Hodgkin lymphomas. , 2003, Blood.

[26]  J. Hainsworth,et al.  Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Wilson,et al.  Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. , 2002, Blood.

[28]  R. Dillman.  Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Döhner,et al.  Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. , 2002, The New England journal of medicine.

[30]  E. Kimby,et al.  Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). , 2002, Blood.

[31]  J. Gribben,et al.  T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. , 2002, Blood.

[32]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[33]  W. Figg,et al.  Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer , 2002, Investigational New Drugs.

[34]  J. Byrd,et al.  Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma , 2002, Cancer.

[35]  A. Rawstron,et al.  Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. , 2002, Blood.

[36]  A. Bass,et al.  Alemtuzumab in Relapsed or Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia , 2002, Leukemia & lymphoma.

[37]  P. Feugier,et al.  Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. , 2001, Blood.

[38]  D. Huhn,et al.  Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. , 2001, Blood.

[39]  M. Grever,et al.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  H. Kantarjian,et al.  Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  B. Cheson,et al.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[42]  M. Kaminski,et al.  Iodine-131 Tositumomab For Patients With Small Lymphocytic Lymphoma (SLL): Overall Clinical Trial Experience , 2000 .

[43]  H. Muller-Hermelink,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Dyer,et al.  The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. , 1999, Seminars in oncology.

[45]  M. Czuczman,et al.  Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  J. Byrd,et al.  Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Amess,et al.  IDEC‐C2B8 anti‐CD20 (Rituximab) immunotherapy in patients with low‐grade non‐Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients , 1999, European journal of haematology.

[48]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  B. Cheson,et al.  Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  L. Ginaldi,et al.  Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. , 1998, Leukemia research.

[51]  D. Maloney,et al.  IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .

[52]  M. Dyer,et al.  Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  D. Catovsky,et al.  Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia , 1997, British journal of haematology.

[54]  A. König,et al.  Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis , 1997, Leukemia.

[55]  M. Dyer,et al.  Humanized CD52 monoclonal antibody campath‐1H as first‐line treatment in chronic lymphocytic leukaemia , 1996, British journal of haematology.

[56]  Knox,et al.  Radioimmunotherapy of the Non-Hodgkin's Lymphomas. , 1995, Seminars in radiation oncology.

[57]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[58]  G. Hale,et al.  The CAMPATH-1 antigen (CDw52). , 1990, Tissue antigens.

[59]  G. Denardo,et al.  Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. , 1990, Cancer research.

[60]  M. Dyer,et al.  Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. , 1989, Blood.

[61]  S. Martin,et al.  A phase 1a clinical trial of LYM‐1 monoclonal antibody serotherapy in patients with refractory b cell malignancies , 1989, Hematological oncology.

[62]  C. Haanen,et al.  The development of non‐responsiveness to immunotherapy with monoclonal anti‐idiotypic antibodies in a patient with B‐CLL , 1988, British journal of haematology.

[63]  M. Borowitz,et al.  A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. , 1988, Journal of biological response modifiers.

[64]  J. Winter,et al.  Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. , 1987, Cancer research.

[65]  R. Dillman,et al.  Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  S. Kon,et al.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. , 1982, The New England journal of medicine.

[67]  D. Kufe,et al.  Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. , 1980, Cancer research.

[68]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[69]  K.,et al.  Effects of Therapy With TIOl Ricin A-Chain Immunotoxin in Two Leukemia Patients , 2005 .

[70]  J. Byrd,et al.  Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. , 2005, Blood.

[71]  H. Döhner,et al.  Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL: CLL2H study of the German CLL Study Group (GCLLSG) , 2005 .

[72]  Thomas S. Lin,et al.  FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. , 2005, Blood.

[73]  R. Dillman.  Infusion Reactions Associated with the Therapeutic Use of Monoclonal Antibodies in the Treatment of Malignancy , 2004, Cancer and Metastasis Reviews.

[74]  J. Byrd,et al.  Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). , 2003, Blood.

[75]  B. Coiffier,et al.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  M. Dyer,et al.  Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies. , 1990, Leukemia & lymphoma.

[77]  C. Haanen,et al.  Treatment of chronic lymphocytic leukaemia with monoclonal anti-idiotypic antibody. , 1985, The Netherlands journal of medicine.

[78]  J. Ritz,et al.  A unique cell surface antigen identifying lymphoid malignancies of B cell origin. , 1981, The Journal of clinical investigation.

[79]  P. Ehrlich,et al.  Croonian lecture.—On immunity with special reference to cell life , 1900, Proceedings of the Royal Society of London.